The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck

Summary Antigen specific stimulation of immune cells, triggers expression of a diverse array of co-signaling molecules that help define the fate of the resultant immune response. Antibodies and fusion proteins, capable of blocking and/or activating these co-signaling pathways, are emerging as potent...

Full description

Saved in:
Bibliographic Details
Published in:Oral oncology 2014-07, Vol.50 (7), p.627-632
Main Authors: Zandberg, Dan P, Strome, Scott E
Format: Article
Language:English
Subjects:
B7-H1
B7-H1 Antigen - metabolism
Biological and medical sciences
Carcinoma, Squamous Cell - immunology
Carcinoma, Squamous Cell - metabolism
Dermatology
Head and neck
Head and Neck Neoplasms - immunology
Head and Neck Neoplasms - metabolism
Hematology, Oncology and Palliative Medicine
Humans
Immunotherapy
Medical sciences
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Otolaryngology
Otorhinolaryngology. Stomatology
PD-1
PD-L1
Programmed Cell Death 1 Receptor - metabolism
Signal Transduction
Squamous
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Antigen specific stimulation of immune cells, triggers expression of a diverse array of co-signaling molecules that help define the fate of the resultant immune response. Antibodies and fusion proteins, capable of blocking and/or activating these co-signaling pathways, are emerging as potent therapeutic options for the treatment of cancer and autoimmune disease. Blockade of one such pair of co signaling interactions, termed PD-L1:PD-1, has shown tremendous promise in phase I treatment trials for advanced solid tumors like non-small cell lung cancer and melanoma, with long term disease remission in select patients. Based on intriguing preclinical data from our group and others, several trials are actively evaluating the utility of PD-L1:PD-1 blockade for the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). In this review we will explore what is known about the interactions between PD-1 and PD-L1, with a focus on SCCHN, and specifically discuss how this pathway can be manipulated with therapeutic intent.
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2014.04.003